News Release

Patent Cites Viraffinity™ for Dengue Virus (DV) Purification

MONMOUTH JUNCTION, NJ, July 31, 2018 -- Biotech Support Group reports on a recent patent describing the simplicity and efficiency of their virus enrichment technology for viral proteomic analyses from plasma. 

The citation is:

Bedin, Frédéric, and Romain Fragnoud. "Method and kit for determining the probability that a patient will develop a severe case of dengue." U.S. Patent Application No. 15/912,730.

In brief, the patent application describes claims determining whether a patient will develop severe dengue based on a blood sample. In the example, virions were purified from plasma pools of patients with dengue fever or severe dengue. For purification, virions were first enriched by ultracentrifugation and then subsequently purified by Viraffinity™. The patent application states “…resuspension is then purified using an insoluble polyelectrolyte, Viraffinity (BioSupportGroup, USA). For this purpose, 200 microliters of an MN buffer (60 mM MES pH 6.5, 150 mM NaCl) are added to the viral suspension along with 100 microliters of Viraffinity. The mixture is incubated for 5 min at room temperature then centrifuged for 10 min at 1000×g, following supplier instructions. The supernatant is removed and the polymer pellet is rinsed 3 times with 200 microliters of MN buffer. …The presence of the virus in the final samples was verified by immunoblotting with a monoclonal antibody directed against the envelope protein of the dengue virus (E protein).”.

“This patent application follows previously reported research whereby Viraffinity™ complements the gold-standard of enrichment using gradient ultracentrifugation. I am very pleased that the exquisite selectivity profile of Viraffinity™ was in-part the reason the patent’s authors were able to obtain an excellent viral protein signal by Western blot” states Swapan Roy, Ph.D., President and Founder of Biotech Support Group. 

For more information visit: Viraffinity™, at
http://www.biotechsupportgroup.com/Viraffinity-Virus-and-Viral-Component-Isolation-p/v1062.htm

About Biotech Support Group LLC

Converging with cultural and technological disruptions forthcoming in healthcare, Biotech Support Group develops methods for cost effective and efficient sample prep essential for these expanding markets. Following a tiered business strategy, the company continues its growth in the consumable research products area supporting the rapidly expanding installation of LC-MS instrument and computational infrastructure. For this market, key products include: AlbuVoid™ and AlbuSorb™ for albumin depletion, Cleanascite™ for lipid adsorption, HemogloBind™ and HemoVoid™ for hemoglobin removal, and NuGel™ for functional proteomics. From these innovations, the company has acquired knowledgebase and biomarker intellectual property assets that support discoveries of protein markers from blood, with special emphasis on early detection and personalized medical decisions for cancer patients. For more information, go to http://www.biotechsupportgroup.com

Contact:
Matthew Kuruc 732-274-2866, mkuruc@biotechsupportgroup.com